Open AccessLevels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People
Author(s) -
Vishwal Indravadan Patel,
Kaustubh Patel,
Mayur Goradhanbhai Makadia,
Aashna Darshanbhai Shah,
K. S. Chaudhari,
Haridas Neelakandan Nilayangode
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/22741.9258
Subject(s) - dyslipidemia , medicine , apolipoprotein b , glycemic , diabetes mellitus , lipid profile , lipoprotein(a) , endocrinology , lipoprotein , apolipoprotein a1 , metabolic control analysis , cholesterol
Diabetes Mellitus (DM) is always a multifactorial metabolic disorder having a wide range of abnormalities in carbohydrate, lipid and protein metabolism. Dyslipidemia is a natural process of DM causing abnormal variations of different lipoproteins and it is one of the significant risk factors for Cardiovascular Disorder (CVD). There is a need to closely evaluate newer approaches in case of DM because even if dyslipidemia is treated, there is always a risk of CVDs in DM patients because of the hyperglycemia itself. So, lipid abnormalities should be assessed aggressively and treated as part of diabetes care. Apolipoprotein B100 (Apo B100), Apolipoprotein A1 (Apo A1) and Lipoprotein (a) {Lp(a)} are newer markers which are always welcome and necessary as many of the reported cases with normal conventional lipid profile have developed cardiac events.